iA Global Asset Management Inc. Sells 45,773 Shares of Pfizer Inc. (NYSE:PFE)

iA Global Asset Management Inc. lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 71.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,481 shares of the biopharmaceutical company's stock after selling 45,773 shares during the quarter. iA Global Asset Management Inc.'s holdings in Pfizer were worth $535,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its stake in Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after buying an additional 12,864,343 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company's stock valued at $150,481,000 after acquiring an additional 8,378,173 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Pfizer by 22.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. International Assets Investment Management LLC bought a new stake in Pfizer during the third quarter worth about $146,481,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Pfizer by 164.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,316,405 shares of the biopharmaceutical company's stock valued at $211,737,000 after purchasing an additional 4,546,809 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 2.0 %

Pfizer stock traded down $0.52 during trading hours on Tuesday, hitting $25.58. The stock had a trading volume of 43,228,141 shares, compared to its average volume of 38,528,086. The business's 50 day simple moving average is $27.42 and its 200-day simple moving average is $28.36. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $144.96 billion, a price-to-earnings ratio of 34.55, a P/E/G ratio of 0.70 and a beta of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company's revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company posted ($0.17) EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 2nd. Shareholders of record on Friday, November 8th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.57%. The ex-dividend date was Friday, November 8th. Pfizer's dividend payout ratio is presently 227.03%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Evercore ISI raised shares of Pfizer to a "strong-buy" rating in a research report on Wednesday, October 30th. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 price objective for the company. Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They issued an "underperform" rating and a $25.00 target price on the stock. Finally, Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They set a "neutral" rating and a $30.00 price target for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.64.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.